【研报掘金丨国证国际：恒瑞医药为领先创新型制药企业予港股IPO专用评级“6.1”】国证国际研报指出，恒瑞医药(1276.HK)是一家根植中国、全球领先的创新型制药企业。2024年公司营收279.85亿元（+22.6%）、归母净利润63.37亿元（+47.3%），毛利率提升1.6pct至86.2%。核心增长引擎为创新药收入，创新药销售收入占总收入的百分比由2022年的38.1%增至2023年的43.4%，并进一步增至2024年的46.3%。其中PD-L1&TGF-β、HER2ADC等重磅品种即将持续放量，叠加海外授权合作，形成“国内放量+海外授权”双轮驱动。公司此次IPO发行价为41.45-44.05港元，较A股股价有24-28%的折价，对应24年PE为40x-42.4x。公司研发实力雄厚，定价相较A股有较大折扣，且近期港股市场打新热情较为高涨，综合考虑给予IPO专用评级“6.1”。

金融界

May 16, 2025

国证国际研报指出，恒瑞医药(1276.HK)是一家根植中国、全球领先的创新型制药企业。2024年公司营收279.85亿元（+22.6%）、归母净利润63.37亿元（+47.3%），毛利率提升1.6pct至86.2%。核心增长引擎为创新药收入，创新药销售收入占总收入的百分比由2022年的38.1%增至2023年的43.4%，并进一步增至2024年的46.3%。其中PD-L1&TGF-β、HER2ADC等重磅品种即将持续放量，叠加海外授权合作，形成“国内放量+海外授权”双轮驱动。公司此次IPO发行价为41.45-44.05港元，较A股股价有24-28%的折价，对应24年PE为40x-42.4x。公司研发实力雄厚，定价相较A股有较大折扣，且近期港股市场打新热情较为高涨，综合考虑给予IPO专用评级“6.1”。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2535358846"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2535358846\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2535358846?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-05-16 14:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2535358846","market":"hk","top_or_hot":-1,"title":"【研报掘金丨国证国际：恒瑞医药为领先创新型制药企业 予港股IPO专用评级“6.1”】国证国际研报指出，恒瑞医药(1276.HK)是一家根植中国、全球领先的创新型制药企业。2024年公司营收279.85亿元（+22.6%）、归母净利润63.37亿元（+47.3%），毛利率提升1.6pct至86.2%。核心增长引擎为创新药收入，创新药销售收入占总收入的百分比由2022年的38.1%增至2023年的43.4%，并进一步增至2024年的46.3%。其中PD-L1&TGF-β、HER2ADC等重磅品种即将持续放量，叠加海外授权合作，形成“国内放量+海外授权”双轮驱动。公司此次IPO发行价为41.45-44.05港元，较A股股价有24-28%的折价，对应24年PE为40x-42.4x。公司研发实力雄厚，定价相较A股有较大折扣，且近期港股市场打新热情较为高涨，综合考虑给予IPO专用评级“6.1”。","media":"金融界","content":"<html><body><div>国证国际研报指出，<span><a href=\"https://laohu8.com/S/600276\">恒瑞医药</a></span>(1276.HK)是一家根植中国、全球领先的创新型制药企业。2024年公司营收279.85亿元（+22.6%）、归母净利润63.37亿元（+47.3%），毛利率提升1.6pct至86.2%。核心增长引擎为创新药收入，创新药销售收入占总收入的百分比由2022年的38.1%增至2023年的43.4%，并进一步增至2024年的46.3%。其中PD-L1&amp;TGF-β、HER2ADC等重磅品种即将持续放量，叠加海外授权合作，形成“国内放量+海外授权”双轮驱动。公司此次IPO发行价为41.45-44.05港元，较A股股价有24-28%的折价，对应24年PE为40x-42.4x。公司研发实力雄厚，定价相较A股有较大折扣，且近期港股市场打新热情较为高涨，综合考虑给予IPO专用评级“6.1”。</div></body></html>","source":"jinrongjie_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>【研报掘金丨国证国际：恒瑞医药为领先创新型制药企业 予港股IPO专用评级“6.1”】国证国际研报指出，恒瑞医药(1276.HK)是一家根植中国、全球领先的创新型制药企业。2024年公司营收279.85亿元（+22.6%）、归母净利润63.37亿元（+47.3%），毛利率提升1.6pct至86.2%。核心增长引擎为创新药收入，创新药销售收入占总收入的百分比由2022年的38.1%增至2023年的43.4%，并进一步增至2024年的46.3%。其中PD-L1&TGF-β、HER2ADC等重磅品种即将持续放量，叠加海外授权合作，形成“国内放量+海外授权”双轮驱动。公司此次IPO发行价为41.45-44.05港元，较A股股价有24-28%的折价，对应24年PE为40x-42.4x。公司研发实力雄厚，定价相较A股有较大折扣，且近期港股市场打新热情较为高涨，综合考虑给予IPO专用评级“6.1”。</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n【研报掘金丨国证国际：恒瑞医药为领先创新型制药企业 予港股IPO专用评级“6.1”】国证国际研报指出，恒瑞医药(1276.HK)是一家根植中国、全球领先的创新型制药企业。2024年公司营收279.85亿元（+22.6%）、归母净利润63.37亿元（+47.3%），毛利率提升1.6pct至86.2%。核心增长引擎为创新药收入，创新药销售收入占总收入的百分比由2022年的38.1%增至2023年的43.4%，并进一步增至2024年的46.3%。其中PD-L1&TGF-β、HER2ADC等重磅品种即将持续放量，叠加海外授权合作，形成“国内放量+海外授权”双轮驱动。公司此次IPO发行价为41.45-44.05港元，较A股股价有24-28%的折价，对应24年PE为40x-42.4x。公司研发实力雄厚，定价相较A股有较大折扣，且近期港股市场打新热情较为高涨，综合考虑给予IPO专用评级“6.1”。\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-05-16 14:19 北京时间&nbsp;&nbsp;&nbsp;<a href=https://24h.jrj.com.cn/2025/05/16141950441814.shtml><strong>金融界</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>国证国际研报指出，恒瑞医药(1276.HK)是一家根植中国、全球领先的创新型制药企业。2024年公司营收279.85亿元（+22.6%）、归母净利润63.37亿元（+47.3%），毛利率提升1.6pct至86.2%。核心增长引擎为创新药收入，创新药销售收入占总收入的百分比由2022年的38.1%增至2023年的43.4%，并进一步增至2024年的46.3%。其中PD-L1&TGF-β、...</p>\n\n<a href=\"https://24h.jrj.com.cn/2025/05/16141950441814.shtml\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"600276","symbol_name":"恒瑞医药","start_time":0,"source_url":"https://24h.jrj.com.cn/2025/05/16141950441814.shtml","article_id":"2535358846","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2535358846","pubTimestamp":1747376389,"columns":[],"sourceInfo":{"source_id":"jinrongjie_stock","name":"金融界"},"weMediaInfo":null,"summary":"2024年公司营收279.85亿元、归母净利润63.37亿元，毛利率提升1.6pct至86.2%。核心增长引擎为创新药收入，创新药销售收入占总收入的百分比由2022年的38.1%增至2023年的43.4%，并进一步增至2024年的46.3%。公司此次IPO发行价为41.45-44.05港元，较A股股价有24-28%的折价，对应24年PE为40x-42.4x。公司研发实力雄厚，定价相较A股有较大折扣，且近期港股市场打新热情较为高涨，综合考虑给予IPO专用评级“6.1”。","collect":0,"end_time":0,"defaultTopTitle":"jrj.com.cn","property":["rate","earning"],"viewcount":null,"language":"zh","relate_stocks":{"159982":"中证500","159992":"创新药","399300":"沪深300","600276":"恒瑞医药","06978":"永泰生物-B","01276":"恒瑞医药","PD":"PagerDuty, Inc.","HSTECH":"恒生科技指数","01477":"欧康维视生物-B","YANG":"三倍做空富时中国ETF-Direxion","HSCEI":"国企指数"},"translate_title":"[Research Report Nuggets | China Securities International: Hengrui Medicine is a leading innovative pharmaceutical company and gives Hong Kong stock IPO a special rating of \"6.1\"] China Securities International Research Report pointed out that Hengrui Medicine (1276. HK) is a leading company rooted in China and in the world. Innovative pharmaceutical companies. In 2024, the company's revenue will be 27.985 billion yuan (22.6%), the net profit attributable to the parent company will be 6.337 billion yuan (47.3%), and the gross profit margin will increase by 1.6 pct to 86.2%. The core growth eng","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159982":1,"159992":1,"399300":1,"600276":1,"YANG":1,"01276":1,"06978":1,"PD":1,"HSTECH":1,"HSCEI":1,"01477":1},"content_text":"国证国际研报指出，恒瑞医药(1276.HK)是一家根植中国、全球领先的创新型制药企业。2024年公司营收279.85亿元（+22.6%）、归母净利润63.37亿元（+47.3%），毛利率提升1.6pct至86.2%。核心增长引擎为创新药收入，创新药销售收入占总收入的百分比由2022年的38.1%增至2023年的43.4%，并进一步增至2024年的46.3%。其中PD-L1&TGF-β、HER2ADC等重磅品种即将持续放量，叠加海外授权合作，形成“国内放量+海外授权”双轮驱动。公司此次IPO发行价为41.45-44.05港元，较A股股价有24-28%的折价，对应24年PE为40x-42.4x。公司研发实力雄厚，定价相较A股有较大折扣，且近期港股市场打新热情较为高涨，综合考虑给予IPO专用评级“6.1”。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}